Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Kaserer

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
Liver|February 13, 2001
18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liverA Kurtaran, A Becherer, F Pfeffel, et al.
International Journal of Cancer|March 29, 2001
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphyS Li, M Peck-Radosavljevic, E Koller, et al.
Cancer Research|May 15, 1998
Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829I Virgolini, M Leimer, H Handmaker, et al.
European Journal of Nuclear Medicine|October 1, 1996
In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCTI Virgolini, P Angelberger, S Li, et al.
Endocrinology|October 28, 1999
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapyP M Smith-Jones, C Bischof, M Leimer, et al.
Nuclear Medicine and Biology|August 1, 1996
123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractI Virgolini, M Raderer, A Kurtaran, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
Liver|February 13, 2001
18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liverA Kurtaran, A Becherer, F Pfeffel, et al.
International Journal of Cancer|March 29, 2001
Characterization of (123)I-vascular endothelial growth factor-binding sites expressed on human tumour cells: possible implication for tumour scintigraphyS Li, M Peck-Radosavljevic, E Koller, et al.
Cancer Research|May 15, 1998
Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829I Virgolini, M Leimer, H Handmaker, et al.
European Journal of Nuclear Medicine|October 1, 1996
In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCTI Virgolini, P Angelberger, S Li, et al.
Endocrinology|October 28, 1999
DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapyP M Smith-Jones, C Bischof, M Leimer, et al.
Nuclear Medicine and Biology|August 1, 1996
123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractI Virgolini, M Raderer, A Kurtaran, et al.
Pageof 7